• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2018/09/13
Shionogi and Rohto Pharmaceutical Co.,Ltd. Enter into Lisence Agreement regarding “Cellular and Tissue-based Products” Candidate ADR-001
2018/09/12
Shionogi to Announce Corporate Reorganization and Personnel Reassignment
2018/09/10
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
2018/09/07
The Dispute with the Boards of Appeal of the Japanese Patent Office between MSD regarding HIV Integrase Inhibitor
2018/09/06
Baloxavir Marboxil Phase II and III Studies for the Treatment of Influenza Published in the New England Journal of Medicine
2018/08/31
Shionogi Announces U.S. Availability of Mulpleta® (Lusutrombopag) for the Treatment of Thrombocytopenia in Adults with Chronic Liver Disease Scheduled to Undergo a Procedure
2018/08/10
Shionogi Submits New Drug Application of INTUNIV® in Japan for Treatment of Adult ADHD
2018/08/09
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
2018/08/06
Audio webcasting: First Quarter of FY2018 Financial Results
2018/08/02
Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag)
2018/07/30
Financial Results for the First Quarter of FY2018
2018/07/30
Notice Regarding Acquisition of Own Shares and Cancellation of Treasury Shares(Acquisition of own shares pursuant to the provisions of Article 165, paragraph 2 of the Companies Act and cancellation of treasury stocks pursuant to the provisions of Article 178 of the Companies Act)
2018/07/23
Notice of Revisions to Earnings Forecasts